The 5q- syndrome: biology and treatment. (Q54539679)

31 May 2018

title

The 5q- syndrome: biology and treatment. (English)

1 reference

31 May 2018

author name string

Eric Padron

series ordinal

1 reference

31 May 2018

Rami Komrokji

series ordinal

1 reference

31 May 2018

Alan F List

series ordinal

1 reference

31 May 2018

publication date

1 December 2011

1 reference

31 May 2018

Current Treatment Options in Oncology

published in

1 reference

31 May 2018

volume

1 reference

31 May 2018

issue

1 reference

31 May 2018

page(s)

354-368

1 reference

31 May 2018

Distinct haematological disorder with deletion of long arm of no. 5 chromosome

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Van-den Berghe's 5q- syndrome in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Ribosomal protein gene sequences map to human chromosomes 5, 8, and 17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Primary structure of human ribosomal protein S14 and the gene that encodes it

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Linkage of the leuS, emtB, and chr genes on chromosome 5 in humans and expression of human genes encoding protein synthetic components in human--Chinese hamster hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Ribosomopathies: human disorders of ribosome dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Cell biology: Arrest by ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Two mouse genes encoding potential transcription factors with identical DNA-binding domains are activated by growth factors in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Structure of the Dimerization and β-Catenin- Binding Region of α-Catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Alpha-catenin is essential in intestinal adenoma formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Complementation of the mitotic activator, p80cdc25, by a human protein-tyrosine phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

p38(MAPK): stress responses from molecular mechanisms to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Signaling to p53: ribosomal proteins find their way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0165-1

Mutation analysis of the SPARC gene in the 5q-syndrome

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.

1 reference

12 December 2020

Gene expression profiling of CD34+cells in patients with the 5q− syndrome

1 reference

12 December 2020

Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q

1 reference

12 December 2020

Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation

1 reference

12 December 2020

Molecular Mapping of Uncharacteristically Small 5q Deletions in Two Patients with the 5q- Syndrome: Delineation of the Critical Region on 5q and Identification of a 5q- Breakpoint

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

Localization of the genes encoding the catalytic subunits of protein phosphatase 2A to human chromosome bands 5q23-->q31 and 8p12-->p11.2, respectively

1 reference

12 December 2020

Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome

1 reference

12 December 2020

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

1 reference

12 December 2020

10.1007/S11864-011-0165-1

Identifiers

DOI

1 reference

31 May 2018

1 reference

31 May 2018